journal article·2017-07-04Open access

Lipid-based dispersions of exemestane for improved dissolution rate and intestinal permeability: in vitro and ex vivo characterization

Basanth Babu Eedara, Suresh Bandari

Abstract

Current study aimed to develop lipid dispersions of poorly water soluble exemestane by employing lipid carriers such as Gelucire 44/14 and TPGS with porous calcium silicate (PCS) as an adsorbent carrier and formulate into a solid dosage form. The lipid dispersions at 1:5 ratio showed the highest solubility and dissolution compared to pure exemestane. Further, the ex vivo intestinal permeation studies showed improved apparent permeability (Papp, cm/s) of exemestane from the lipid dispersions (GLD1:5 1.3 × 10−2 cm/s; TLD1:5 1.8 × 10−2 cm/s) compared to pure exemestane (0.7 × 10−2 cm/s). The optimized lipid dispersions (GLD1:5 and TLD1:5) were evaluated for scalability to develop into capsules.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Drug Solubulity and Delivery Systems · Advanced Drug Delivery Systems · Analytical Methods in Pharmaceuticals

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, St. Peter’s Institute of Pharmaceutical Sciences, Vidyanagar, Warangal, Telangana, India

Funding

Science and Engineering Research Board

References (41)

Show source-provided references
1. 10.1007/s12247-014-9181-610.1007/s12247-014-9181-6 ↗
2. 10.1007/s11814-012-0133-x10.1007/s11814-012-0133-x ↗
3. 10.1016/j.tca.2005.09.01110.1016/j.tca.2005.09.011 ↗
4. Carr RL. · Chem Eng · 1965 · 72 · 163
5. 10.1023/A:101500050362910.1023/A:1015000503629 ↗
6. 10.4155/tde.15.4310.4155/tde.15.43 ↗
7. 10.1007/s40005-013-0069-010.1007/s40005-013-0069-0 ↗
8. 10.3109/03639045.2013.80198410.3109/03639045.2013.801984 ↗
9. 10.1002/jps.2266610.1002/jps.22666 ↗
10. 10.1016/j.bbalip.2008.05.00610.1016/j.bbalip.2008.05.006 ↗
11. 10.1002/jps.2397910.1002/jps.23979 ↗
12. 10.3109/10837450.2014.90830610.3109/10837450.2014.908306 ↗
13. 10.1016/j.jsbmb.2007.05.02310.1016/j.jsbmb.2007.05.023 ↗
14. 10.1016/S0378-5173(01)00891-210.1016/S0378-5173(01)00891-2 ↗
15. Higuchi J · Adv Anal Chem Instrum · 1965 · 4 · 117
16. 10.1016/j.ejps.2015.03.02410.1016/j.ejps.2015.03.024 ↗
17. 10.1007/s40005-013-0060-910.1007/s40005-013-0060-9 ↗
18. 10.1016/j.farmac.2005.04.01410.1016/j.farmac.2005.04.014 ↗
19. 10.1200/JCO.2000.18.7.139910.1200/JCO.2000.18.7.1399 ↗
20. 10.1002/jps.2006710.1002/jps.20067 ↗
21. 10.1016/S0378-5173(00)00485-310.1016/S0378-5173(00)00485-3 ↗
22. Kristina SB · J Pharm Pharm Sci · 2007 · 10 · 319
23. 10.1016/S0939-6411(00)00091-610.1016/S0939-6411(00)00091-6 ↗
24. 10.1016/j.supflu.2006.03.02710.1016/j.supflu.2006.03.027 ↗
25. 10.1016/j.ijpharm.2014.11.00110.1016/j.ijpharm.2014.11.001 ↗
26. 10.1016/j.ijpharm.2010.12.03510.1016/j.ijpharm.2010.12.035 ↗
27. 10.1016/j.apt.2010.09.01810.1016/j.apt.2010.09.018 ↗
28. 10.3109/03639045.2014.90008110.3109/03639045.2014.900081 ↗
29. 10.1021/js980403l10.1021/js980403l ↗
30. 10.1016/S0168-3659(02)00492-310.1016/S0168-3659(02)00492-3 ↗
31. 10.1208/s12249-008-9080-610.1208/s12249-008-9080-6 ↗
32. 10.1007/s11814-015-0205-910.1007/s11814-015-0205-9 ↗
33. 10.1023/A:101216741037610.1023/A:1012167410376 ↗
34. van den Mooter G · Int J Pharm Sci · 2006 · 26 · 219
35. 10.1002/chin.20074527010.1002/chin.200745270 ↗
36. Yavuz B · FABAD J Pharm Sci · 2007 · 32 · 79
37. 10.1016/j.ijpharm.2010.07.04610.1016/j.ijpharm.2010.07.046 ↗
38. 10.1023/A:101893900678010.1023/A:1018939006780 ↗
39. 10.1248/cpb.42.232710.1248/cpb.42.2327 ↗
40. 10.1016/S0939-6411(03)00142-510.1016/S0939-6411(03)00142-5 ↗
41. 10.1016/j.ijpharm.2014.01.02310.1016/j.ijpharm.2014.01.023 ↗